Clinical trials: Carcinoma, Non-Small-Cell Lung
Locally Advanced Non-Small Cell Lung Cancer, Chemoradiotherapy
Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy
For patients with irresectable locally advanced non-small cell lung cancer (NSCLC) (e.g. multilevel or bulky N2 disease or presence of N3 lymph node metastases), current guidelines recommend treatment with chemoradiotherapy (CRT)…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Chemoradiotherapy, Cavitation Lung, Surgery
- Trial name
- UPLAN-I (NCT05620199)
- Testing
- Upfront resection
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Small Cell Lung Cancer, Small Cell Lung Carcinoma
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete).
- Trial name
- NCT00445198
- Testing
- ABT-263
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation
- Trial name
- NCT01089998
- Testing
- BAY86-9596, Fludeoxyglucose (18F)-IBA
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Ovarian Cancer, Breast Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced…
- Conditions
- Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
- Trial name
- LNCB74-01 (NCT06774963)
- Testing
- LNCB74
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- LigaChem Biosciences, Inc.
Metastatic Non-small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
- Trial name
- TROPION-Lung15 (NCT06417814)
- Testing
- Dato-DXd, Osimertinib, Pemetrexed
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 768 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX301…
- Trial name
- NCT05102214
- Testing
- HLX301
- Where
- 5 sites in Australia
- Volunteers
- 150 people
- Sponsor
- Shanghai Henlius Biotech
Lung Cancer (NSCLC), Radiation
GCC 2546- Motion Management
The purpose of this study is to assess a real time motion tracking of lung tumors and important organs next to the tumor while breathing during a participant's radiation treatment.
- Trial name
- NCT07398209
- Testing
- MRI
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Maryland, Baltimore
Non-Small Cell Lung Cancer, Chronic Obstructive Lung Disease
Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)
People who have undergone curative surgery for non-small cell lung cancer (NSCLC) often experience reduced quality of life (QoL), a high burden of symptoms, and physical deconditioning.
- Trial name
- Sing-a-Lung 2 (NCT07460999)
- Testing
- Singing training (Singing for Lung Health (SLH)), Control group: Usual care
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Zealand University Hospital
Non-small Cell Lung Cancer (NSCLC) Stage III
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-specific immunotherapy (L-BLP25) administered as weekly subcutaneous doses over 8 weeks following a single dose of intravenous cyclophosphamide (CPA)…
- Trial name
- FINGERPRINT (NCT01731587)
- Testing
- Biological: MUC1 peptide specific immunotherapy, Cyclophosphamide (CPA)
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
The goal of this clinical trial is to investigate the use of [89Zr]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06439914
- Testing
- [89Zr]Zr-DFO-emapalumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nerissa T. Viola
Carcinoma, Non-Small-Cell Lung
Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung
This trial is to study the efficacy of nab-PC vs. GC and evaluate toxicity of nab-PC in advanced squamous cell cancer of lung. The correlation between the efficacy of nab-PC and some biomarkers is also to be evaluated.
- Trial name
- C-TONG1002 (NCT01236716)
- Testing
- Albumin paclitaxel plus carboplatin, Gemcitabine plus carboplatin
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Chinese Society of Lung Cancer
Non-small Cell Lung Cancer, Melanoma
PD-L1 Expression in Cancer (PECan Study).
Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study.
- Trial name
- PECan (NCT04436406)
- Testing
- [99mTc]-NM-01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Non Small Cell Lung Cancer, T790M
Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC
The single-arm phase II APOLLO study demonstrated favorable antitumor activity and an acceptable safety profile for aumolertinib in patients with EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer after…
- Conditions
- Non Small Cell Lung Cancer, T790M, EGFR Activating Mutation
- Trial name
- AUMO-RWE (NCT07838532)
- Testing
- Aumolertinib monotherapy （development code: HS-10296）
- Where
- China
- Volunteers
- 637 people
- Sponsor
- Xin Li
Non-small Cell Lung Cancer
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung…
- Trial name
- NCT04332367
- Testing
- Carboplatin, Paclitaxel, Ramucirumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
Predicting relapse and overall survival in potentially resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) patients remains challenging.
- Trial name
- NCT06267144
- Testing
- Sintilimab plus chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Carcinoma, Non-Small-Cell Lung
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with…
- Trial name
- PAPILLON (NCT04538664)
- Testing
- Amivantamab, Pemetrexed, Carboplatin
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC
Small Cell Lung Cancer
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial evaluating the efficacy and safety of Apatinib for third-line and later treatment of patients with small cell lung cancer.
- Trial name
- NCT02995187
- Testing
- Apatinib Mesylate tablet
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of…
- Trial name
- NA_00092076 (NCT02259621)
- Testing
- Nivolumab, Carboplatin, Paclitaxel
- Where
- 5 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes and/or to distant parts of the body and that are…
- Trial name
- NCT05537740
- Testing
- BAY3375968, Pembrolizumab
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 129 people
- Sponsor
- Bayer
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.